Replies to post #75715 on Regen BioPharma Inc (RGBP)

[Carter]

I agree Ez - and that write-up comes from a team of research scientists that have nothing at all to do with Regen Biopharma. This is independent confirmation of the value in NR2F6 therapies for the treatment of cancer. For an academic paper it's striking how it almost seems like they're begging pharma to take this on... anti-tumor effects "not accompanied by any signs of... adverse events."

…these clear anti-tumor immune responses in the Nr2f6-/- therapy groups were not accompanied by any signs of immune-related adverse events (irAE). Thus, our study sets the stage for future clinical validation of NR2F6 targeting as a mechanistically independent and potentially synergistic option to improve the efficacy of immuno-oncology therapies.
https://www.nature.com/articles/s41467-018-04004-2

I can better understand why Skiluc has been concluding many of his posts with, "Hello?"